{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:08:29Z","timestamp":1786975709498,"version":"build-2736575974"},"reference-count":6,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:p>This cross-sectional study examines postmarket safety actions for novel oncology drugs that received accelerated Food and Drug Administration (FDA) approval.<\/jats:p>","DOI":"10.1001\/jamanetworkopen.2025.53764","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:00:22Z","timestamp":1768320022000},"page":"e2553764","source":"Crossref","is-referenced-by-count":4,"title":["Postmarket Safety Actions for Novel Oncology Drugs Granted FDA\u2019s Accelerated Approval"],"prefix":"10.1001","volume":"9","author":[{"given":"Maryam","family":"Mooghali","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Yale Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT), Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Wallach","sequence":"additional","affiliation":[{"name":"Yale Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT), Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron P.","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Yale Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT), Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut"},{"name":"Center for Outcomes Research and Evaluation, Yale-New Haven Health System, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshma","family":"Ramachandran","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Yale Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT), Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"issue":"5","key":"zld250312r2","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s43441-022-00430-z","article-title":"Analysis of FDA\u2019s accelerated approval program performance December 1992-December 2021.","volume":"56","author":"Beakes-Read","year":"2022","journal-title":"Ther Innov Regul Sci"},{"issue":"18","key":"zld250312r3","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1001\/jama.2017.5150","article-title":"Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010.","volume":"317","author":"Downing","year":"2017","journal-title":"JAMA"},{"key":"zld250312r4","doi-asserted-by":"crossref","first-page":"j3837","DOI":"10.1136\/bmj.j3837","article-title":"Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study.","volume":"358","author":"Mostaghim","year":"2017","journal-title":"BMJ"},{"issue":"10","key":"zld250312r5","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/jnci\/djaf195","article-title":"Assessing outcomes emerging after conversion to regular approval for cancer drug indications granted accelerated approval, 1992-2021.","volume":"117","author":"Tibau","year":"2025","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"zld250312r6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.33601","article-title":"Comparison of duration of postapproval vs pivotal trials for therapeutic agents granted US Food and Drug Administration accelerated approval, 2009-2018.","volume":"4","author":"Wallach","year":"2021","journal-title":"JAMA Netw Open"},{"key":"zld250312r1","unstructured":"US Food and Drug Administration. Accelerated approval. Updated February 24, 2023. Accessed June 1, 2025. https:\/\/www.fda.gov\/patients\/fast-track-breakthrough-therapy-accelerated-approval-priority-review\/accelerated-approval"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2843806\/mooghali_2026_ld_250312_1767723230.64901.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:00:23Z","timestamp":1768320023000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2843806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":6,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.53764","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]}}}